Abstract 3029
Background
Efforts to develop successful immunotherapeutic treatments in pancreatic cancer have failed so far. One possible strategy might be the combination of established chemotherapeutic regimens (FOLFIRINOX or gemcitabine plus nab-paclitaxel [gem/nab-pac]) with checkpoint inhibitors. The goal of the present pilot study is to provide a better understanding of alterations in the expression of T cell activation markers and immune checkpoint molecules in patients with advanced pancreatic cancer receiving FOLFIRINOX or gem/nab-pac.
Methods
We conducted a prospective single-center study with selected advanced pancreatic cancer patients who received FOLFIRINOX or gem/nab-pac between 2015 and 2017. Blood samples (15 ml heparinized blood, 10 ml serum) were taken at day 1 and 30 of first-line chemotherapy. Ficoll density gradient separation was used to isolate peripheral blood mononuclear cells (PBMCs). After short-term storage at -80 °C, flow cytometry was performed using a LSR Fortessa flow cytometer (BD Biosciences). CD3+ CD4+ and CD3+ CD8+ T cell count as well as the expression of FoxP3, PD-1, CTLA4, CCR7, CD62L, CD69, Tim3 and LAG 3 on CD3+ T cells was analyzed.
Results
25 eligible patients were included in the study. Two consecutive blood samples were available for 21 of these patients (FOLFIRINOX: n = 18, gem/nab-pac: n = 3). We found a broad variability within T cell subsets and change of expression in T cell activation/immune checkpoint molecules during therapy. While the majority of patients (n = 13/21, 62%) is still in follow-up, first results indicate a correlation of an increase of FOXP3+ T cells in peripheral blood during chemotherapy and worse outcome. No correlation between increase of PD-1 on peripheral T cells and prognosis was observed.
Conclusions
A comprehensive RNA based (nanostring nCounter®) analysis of intratumoral immune cell infiltration of all included patients is currently ongoing. It will provide further insights on the interplay between tumoral and peripheral (T cell) immunity during chemotherapy in advanced pancreatic cancer.
Clinical trial identification
Legal entity responsible for the study
Stefan Böck.
Funding
Friedrich-Baur-Stiftung.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract